elfh module, aimed at all healthcare staff who manage or support people who use insulin.
This webinar has useful information all those who manage care for people with diabetes such as GPs, nurses, pharmacists, physicians’ associates and paramedics about the evidence base and prescribing information for Mounjaro®. You will learn about the evidence base for Tirzepatide ( Mounjaro®) a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, for treating type 2 diabetes in line with the recommendations made in
NICE TA924
.
Tirzepatide has a
GREEN
traffic light status for this indication.
(please note it is NOT recommended for weight management but only for treating those with type 2 diabetes)
See Surrey PAD:
Profile : Tirzepatide - Diabetes Mellitus (res-systems.net)
and please note
Mounjaro® is available as a KwikPen® which
contains four weekly doses in one pen which is enough for
ONE MONTH.
The education package is a free online resource for healthcare professionals in primary care. Endorsed by the Primary Care Diabetes Society (PCDS) and Diabetes Technology Network (DTN-UK). Implementing Glucose Sensing in Primary Care, was developed in response to NICE guidance which recommends access to CGM for all people living with type 1 diabetes, and for some people living with type 2 diabetes.
This means that many people throughout the UK will have access to such technology, with many prescriptions coming in primary care. As with all changes in practice, knowledge and confidence for healthcare professionals to safely implement and support is essential.
